195 related articles for article (PubMed ID: 32239692)
61. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
62. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol.
Feliciani C; Zampetti A; Forleo P; Cerritelli L; Amerio P; Proietto G; Tulli A; Amerio P
J Cutan Med Surg; 2004; 8(2):122-5. PubMed ID: 15129317
[TBL] [Abstract][Full Text] [Related]
63. UV-curable gel formulations: Potential drug carriers for the topical treatment of nail diseases.
Kerai LV; Hilton S; Murdan S
Int J Pharm; 2015 Aug; 492(1-2):177-90. PubMed ID: 26187167
[TBL] [Abstract][Full Text] [Related]
64. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study.
Cannavò SP; Guarneri F; Vaccaro M; Borgia F; Guarneri B
Dermatology; 2003; 206(2):153-6. PubMed ID: 12592084
[TBL] [Abstract][Full Text] [Related]
65. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.
Rigopoulos D; Baran R; Chiheb S; Daniel CR; Di Chiacchio N; Gregoriou S; Grover C; Haneke E; Iorizzo M; Pasch M; Piraccini BM; Rich P; Richert B; Rompoti N; Rubin AI; Singal A; Starace M; Tosti A; Triantafyllopoulou I; Zaiac M
J Am Acad Dermatol; 2019 Jul; 81(1):228-240. PubMed ID: 30731172
[TBL] [Abstract][Full Text] [Related]
66. Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment.
Sánchez Regaña M; Márquez Balbás G; Umbert Millet P
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):963-9. PubMed ID: 18410337
[TBL] [Abstract][Full Text] [Related]
67. Interventions for nail psoriasis.
de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI
Cochrane Database Syst Rev; 2013 Jan; (1):CD007633. PubMed ID: 23440816
[TBL] [Abstract][Full Text] [Related]
68. Hydration of nail plate: a novel screening model for transungual drug permeation enhancers.
Chouhan P; Saini TR
Int J Pharm; 2012 Oct; 436(1-2):179-82. PubMed ID: 22705091
[TBL] [Abstract][Full Text] [Related]
69. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study.
De Simone C; Maiorino A; Tassone F; D'Agostino M; Caldarola G
J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):1003-6. PubMed ID: 22788697
[TBL] [Abstract][Full Text] [Related]
70. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
[TBL] [Abstract][Full Text] [Related]
71. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases.
Zakeri M; Valikhani M; Mortazavi H; Barzegari M
Dermatol Online J; 2005 Dec; 11(3):5. PubMed ID: 16409901
[TBL] [Abstract][Full Text] [Related]
72. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study.
Nakamura RC; Abreu Ld; Duque-Estrada B; Tamler C; Leverone AP
An Bras Dermatol; 2012; 87(2):203-11. PubMed ID: 22570023
[TBL] [Abstract][Full Text] [Related]
73. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers.
Khengar RH; Jones SA; Turner RB; Forbes B; Brown MB
Pharm Res; 2007 Dec; 24(12):2207-12. PubMed ID: 17665289
[TBL] [Abstract][Full Text] [Related]
74. Assessment of the nail penetration of antifungal agents, with different physico-chemical properties.
Davies-Strickleton H; Cook J; Hannam S; Bennett R; Gibbs A; Edwards D; Ridden C; Ridden J; Cook D
PLoS One; 2020; 15(2):e0229414. PubMed ID: 32107486
[TBL] [Abstract][Full Text] [Related]
75. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Monti D; Tampucci S; Chetoni P; Burgalassi S; Mailland F
J Drugs Dermatol; 2014 Feb; 13(2):143-7. PubMed ID: 24509963
[TBL] [Abstract][Full Text] [Related]
76. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
Vejnovic I; Huonder C; Betz G
Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
[TBL] [Abstract][Full Text] [Related]
77. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
Elewski BE; Pollak RA; Pillai R; Olin JT
J Drugs Dermatol; 2014 Nov; 13(11):1394-8. PubMed ID: 25607708
[TBL] [Abstract][Full Text] [Related]
78. Influence of human nail etching for the assessment of topical onychomycosis therapies.
Repka MA; Mididoddi PK; Stodghill SP
Int J Pharm; 2004 Sep; 282(1-2):95-106. PubMed ID: 15336385
[TBL] [Abstract][Full Text] [Related]
79. Polyurethanes as New Excipients in Nail Therapeutics.
Valdes BSG; Serro AP; Marto J; Santos RGD; Gómez EC; Otero-Espinar FJ; Bordado JM; Ribeiro HM
Pharmaceutics; 2018 Dec; 10(4):. PubMed ID: 30551686
[TBL] [Abstract][Full Text] [Related]
80. Effect of ablative laser on in vitro transungual delivery.
Nguyen HX; Banga AK
Int J Pharm; 2018 Jun; 544(2):402-414. PubMed ID: 28951347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
